SLC39A5 and metabolic dysfunction-associated steatohepatitis: In contrast, Slc39a5-/- mice challenged with diet-induced NASH displayed significant reductions in serum ALT and AST levels (Figure 6A and B, Figure 6—figure supplement 1A and B) and fasting blood glucose (Figure 6—figure supplement 2B and G), along with significant improvements in hepatic inflammation and fibrosis (Figure 6E and H, Figure 6—figure supplement 1E and H) and the expected increases in serum and hepatic zinc (Figure 6—figure supplement 2C, D, H, I).